加藤健

カトウケン | Kato Ken

所属機関・部署：
職名：頭頸部食道内科/消化管内科科長

研究分野 (1件)：腫瘍診断、治療学

競争的資金等の研究課題 (1件)：

2011 - 2014 抗体医薬品によるインフュージョン反応の発現メカニズム解析と予測系の構築

論文 (283件)：

Motoo Nomura, Toshifumi Yamaguchi, Keisho Chin, Shinji Hato, Ken Kato, Eishi Baba, Hisahiro Matsubara, Hidenori Mukaida, Takako Yoshii, Masahiro Tsuda, et al. Phase II Trial of Adjuvant S-1 Following Neoadjuvant Chemotherapy and Surgery in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: The PIECE Trial. Annals of surgical oncology. 2024
Satoru Matsuda, Hiroya Takeuchi, Ken Kato, Ryunosuke Machida, Yoshinori Ito, Yasuhiro Tsubosa, Hiroyuki Daiko, Kazuo Koyanagi, Takashi Ogata, Takashi Fukuda, et al. Prognostic Impact of Thoracic Duct Resection in Patients Who Underwent Transthoracic Esophagectomy Following Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma: Exploratory Analysis of JCOG1109. Annals of Surgical Oncology. 2024
Shun Yamamoto, Ken Kato, Hiroyuki Daiko, Yoshinori Ito, Takeshi Kajiwara, Takashi Kojima, Hiroshi Miyata, Satoru Nakagawa, Masaki Ueno, Masaya Watanabe, et al. Factors influencing decision-making between surgery and chemoradiotherapy for esophageal carcinoma from the JCOG0502. Future oncology (London, England). 2024. 1-6
Kenro Hirata, Kayo Yoshida, Chikatoshi Katada, Akinori Watanabe, Takahiro Tsushima, Toshifumi Yamaguchi, Sachiko Yamamoto, Hideki Ishikawa, Yasunori Sato, Chiyo K Imamura, et al. Definitive chemoradiotherapy with paclitaxel for locally advanced esophageal squamous cell carcinoma in older patients (PARADISE-1): a phase I trial. BMC cancer. 2024. 24. 1. 873-873
野崎良子, 小熊潤也, 石山廣志朗, 栗田大資, 久保賢太郎, 久保祐人, 宇都宮大地, 伊賀上翔太, 加藤健, 大幸宏幸. 上部消化管術前治療+食道切除後の免疫チェックポイント阻害剤による補助療法の現状食道扁平上皮癌に対する,術前化学療法後の術後nivolumab療法の安全性と有効性. 日本消化器外科学会総会. 2024. 79回. 488-488

MISC (114件)：

Motoo Nomura, Katsuyuki Sakanaka, Ken Kato, Tomohiro Kadota, Yoshinori Ito, Ryunosuke Machida, Keita Sasaki, Tomoko Kataoka, Yasumasa Nishimura, Yuko Kitagawa. A randomized controlled phase III trial of comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal cancer:JCOG1904/ARMADILLO study. JOURNAL OF CLINICAL ONCOLOGY. 2021. 39. 3
Seiichiro Mitani, Ken Kato, Hiroyuki Daiko, Isao Nozaki, Takashi Kojima, Masahiko Yano, Satoru Nakagawa, Masaki Ueno, Masaya Watanabe, Shigeru Tsunoda, et al. Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies: Supplementary analysis of the JCOG trial, JCOG0502. JOURNAL OF CLINICAL ONCOLOGY. 2020. 38. 15
Tomoya Yokota, Ken Kato, Yasuo Hamamoto, Yasuhiro Tsubosa, Hirofumi Ogawa, Yoshinori Ito, Hiroki Hara, Takashi Ura, Takashi Kojima, Keisho Chin, et al. A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer. Annals of surgical oncology. 2020. 27. 2. 460-467
Ken Kato, Byoung Chul Cho, Masanobu Takahashi, Morihito Okada, Chen-Yuan Lin, Keisho Chin, Shigenori Kadowaki, Myung-Ju Ahn, Yasuo Hamamoto, Yuichiro Doki, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. The Lancet. Oncology. 2019. 20. 11. 1506-1517
野村基雄, 清水充子, 大橋真也, 三梨桂子, 加藤健, 小島隆嗣, 坂中克行, 武藤学. 食道癌に対する根治的CRTとNivolumab併用による医師主導治験 Trial in progress. 日本癌治療学会学術集会抄録集. 2019. 57回. P9-5

書籍 (1件)：

術前化学療法と術前化学放射線療法は,効果・安全性の面からどちらが良いか?
医事新報社 2017

講演・口頭発表等 (1件)：

A randomized controlled phase III comparing CF (5-FU, CDDP) versus DCF (5-FU, CDDP, docetaxel) versus CF-RT as neoadjuvant treatment for locally advanced esophageal cancer
(International Symposium of Disease of Esophagus 2018)

※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。登録・更新については、こちらをご覧ください。

前のページに戻る

加藤 健

加藤健